Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 8.7% in October

Aileron Therapeutics, Inc. (NASDAQ:ALRN) was the target of a large decline in short interest in October. As of October 31st, there was short interest totalling 233,300 shares, a decline of 8.7% from the October 15th total of 255,600 shares. Approximately 1.2% of the shares of the company are sold short. Based on an average daily volume of 74,800 shares, the days-to-cover ratio is currently 3.1 days.

Aileron Therapeutics Stock Down 13.3 %

NASDAQ ALRN opened at $2.87 on Friday. The company has a market capitalization of $62.19 million, a P/E ratio of -0.88 and a beta of 2.35. The firm has a 50-day moving average price of $3.48 and a two-hundred day moving average price of $3.13. Aileron Therapeutics has a 12-month low of $1.57 and a 12-month high of $7.42.

Aileron Therapeutics (NASDAQ:ALRN) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.20). Equities analysts expect that Aileron Therapeutics will post -1.41 EPS for the current year.

Institutional Trading of Aileron Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. KG&L Capital Management LLC acquired a new position in shares of Aileron Therapeutics in the third quarter valued at approximately $46,000. Warberg Asset Management LLC acquired a new stake in shares of Aileron Therapeutics in the 2nd quarter valued at about $86,000. Texas Capital Bank Wealth Management Services Inc raised its position in shares of Aileron Therapeutics by 65.9% during the first quarter. Texas Capital Bank Wealth Management Services Inc now owns 26,171 shares of the company’s stock worth $174,000 after purchasing an additional 10,398 shares during the period. Sigma Planning Corp raised its holdings in Aileron Therapeutics by 68.3% during the third quarter. Sigma Planning Corp now owns 212,410 shares of the company’s stock worth $752,000 after buying an additional 86,185 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Aileron Therapeutics by 34.8% in the 3rd quarter. Geode Capital Management LLC now owns 229,817 shares of the company’s stock worth $814,000 after acquiring an additional 59,370 shares during the last quarter. 90.89% of the stock is currently owned by institutional investors.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).